What Is TWST Stock? Twist Bioscience Overview

TWST is the NASDAQ ticker symbol for Twist Bioscience Corporation, a biotechnology company that manufactures synthetic DNA, the molecular building blocks used in pharmaceutical drug discovery, agricultural research, and genomic medicine. Synthetic biology, the science of designing and building DNA sequences from scratch the way software engineers write code to instruct computers, is the field where Twist operates. Founded in 2013 and headquartered in South San Francisco, California, the company went public on the NASDAQ Global Select Market on October 31, 2018. Twist Bioscience sits at the intersection of synthetic biology and genomics, two of the fastest-growing fields in life sciences.

This article covers what Twist Bioscience does, how it makes money, who its competitors are, what the financials look like, and what risks investors should understand before researching the stock further.

This article is for informational purposes only and does not constitute investment advice. Investing in stocks involves risk, including the possible loss of principal. Always conduct your own research and consider consulting a qualified financial advisor before making investment decisions.

TWST Stock: Quick Reference Facts

In This Article:

• The Company Behind the Ticker
• The Technology Explained
• How Twist Makes Money
• Financial Overview
• Who Are the Competitors?
• Key Risks for Investors
• Growth Opportunities
• Frequently Asked Questions
• The Bottom Line

The Company Behind the Ticker: Twist Bioscience's History and Leadership

Twist Bioscience Corporation was founded in 2013 by three scientists who identified a specific problem: manufacturing synthetic DNA was so expensive and slow that it was limiting what biological researchers could accomplish. Emily Leproust, Bill Peck, and Bill Banyai co-founded Twist with the goal of applying silicon chip manufacturing principles to DNA production, bringing the cost and throughput of synthetic DNA in line with what modern research demands.

Emily Leproust, Ph.D., serves as CEO and is the most publicly prominent of the three founders. She holds a doctorate in chemistry and previously worked as a researcher at Agilent Technologies (NYSE: A), a diversified life science instrument company that now competes with Twist in certain product markets. Her scientific credentials are frequently cited in analyst coverage as a key factor in confidence about the company's platform development.

Twist is headquartered in South San Francisco, California, known as "Biotech Bay" and one of the densest concentrations of life sciences companies in the world. The company went public on October 31, 2018, listing on the NASDAQ Global Select Market, the premier tier of the NASDAQ exchange.

What Does Twist Bioscience Actually Do? The Technology Explained

Twist Bioscience's core business is manufacturing synthetic DNA, custom-built sequences of genetic code that scientists order like custom parts for their research. Two foundational concepts make this business legible to non-scientists: synthetic biology and DNA synthesis.

What Is Synthetic Biology?

Synthetic biology is the science of designing and building biological components, most commonly DNA sequences, from scratch rather than extracting them from living organisms. Think of it as programming for living systems: just as software engineers write code to instruct computers, synthetic biologists write DNA sequences to instruct cells. Researchers working in drug discovery, agricultural science, and industrial manufacturing all rely on synthetic biology tools to conduct their work. The global synthetic biology market is projected to grow into the tens of billions of dollars over the coming decade, driven by demand across pharmaceuticals and agriculture as well as bio-based manufacturing, per research cited in McKinsey Global Institute's 2020 Bio Revolution report.

What Is DNA Synthesis?

DNA synthesis is the process of chemically building a DNA strand from scratch, letter by letter, rather than copying it from an existing organism. This is the opposite of DNA sequencing, which reads the order of letters in an existing DNA strand. The distinction matters because companies like Illumina (NASDAQ: ILMN) sequence DNA, meaning they read it, while Twist Bioscience synthesizes DNA, meaning it builds it. These are fundamentally different processes, and Twist's entire business sits on the synthesis side.

How Twist's Silicon Chip Platform Works

Twist Bioscience's manufacturing advantage comes from replacing traditional plastic well-plate synthesis with a silicon chip-based process borrowed from semiconductor manufacturing. Traditional DNA synthesis builds sequences one at a time using individual chemical columns, similar to writing a book letter by letter with a pen. Twist's silicon chip platform prints thousands of distinct DNA sequences simultaneously, the way a printing press runs many copies of a page at once. The company states this approach enables a lower cost-per-base (the price per DNA letter synthesized) than traditional column-based methods at scale, making high-volume products like oligo pools economically feasible.

Twist's Product Portfolio

Twist manufactures five primary product types:

• Oligonucleotides (oligos): An oligonucleotide, or oligo, is a short, custom-made strand of DNA, typically 20 to 200 letters in length. Researchers use oligos as molecular tools in gene editing and diagnostic test development.
• Oligo pools: An oligo pool is a collection of thousands of distinct oligo sequences synthesized together in a single batch. Twist's chip platform makes high-volume oligo pool production cost-effective at a scale that traditional methods could not match.
• Synthetic genes: Longer, complete gene sequences used in pharmaceutical research and protein engineering, ordered by customers who need a specific gene built to specification.
• NGS target enrichment panels: Next-generation sequencing (NGS) is a modern technology that allows scientists to read the genetic code of DNA quickly and at low cost. Before sequencing an entire genome, researchers often use target enrichment panels, kits that isolate only the relevant sections of DNA, to focus the analysis and reduce cost. Twist manufactures and sells these panels for oncology diagnostics and clinical genomics.
• Antibody libraries: An antibody library is a large collection of DNA sequences encoding different antibody variants, used by drug companies to screen for therapeutic candidates. Twist's platform enables synthesis of these libraries at a diversity and scale that supports biopharma drug discovery workflows.

How Does Twist Bioscience Make Money? The Business Model

Twist Bioscience makes money by selling custom-synthesized DNA products directly to pharmaceutical companies, biotechnology firms, academic research institutions, and government laboratories. Like selling picks and shovels during a gold rush, Twist generates revenue by supplying the tools that power biological research regardless of which specific drug or diagnostic product ultimately succeeds.

The company reports two primary commercial segments:

Synbio Products: The core revenue segment, comprising oligo pools, synthetic genes, and variant libraries. Customers order through Twist's digital self-service portal or directly through the sales team. This segment generates the majority of reported revenue.

NGS Products: Revenue from target enrichment panels and related genomics tools for the clinical diagnostics and research genomics market, growing as personalized medicine and oncology testing expand.

Twist Biopharma is a newer business unit that provides antibody discovery libraries and related services to pharmaceutical companies. Biopharma (companies that develop biological drugs, as opposed to small-molecule chemical drugs) customers use these antibody libraries as the starting point for identifying drug candidates. Twist Biopharma is smaller in current revenue than the Synbio segment but targets higher margins through specialized services.

Who buys Twist's DNA, and why:

• Pharmaceutical drug discovery: A biopharma company might order a library of 100,000 different antibody DNA sequences from Twist to screen for candidates that could become a cancer therapy.
• Academic research: University labs use oligo pools and synthetic genes for gene editing experiments and basic biological research.
• Agricultural biotech: Companies developing disease-resistant crops use synthetic gene constructs built by Twist to test biological modifications.
• Industrial biotechnology: Companies engineering bio-based manufacturing processes for fuels and specialty chemicals order synthetic DNA to design the enzymes those processes require.
• NGS diagnostics: Clinical genomics labs use Twist's target enrichment panels to prepare patient DNA samples for sequencing in oncology and rare disease testing. Government and defense research programs, including DARPA-funded synthetic biology initiatives, also appear among Twist's disclosed customer segments.

TWST Stock Financial Overview: Revenue and the Path to Profitability

Twist Bioscience has reported consistent year-over-year revenue growth since its 2018 IPO but has not yet achieved GAAP net profitability as of its most recently filed annual report.

Is Twist Bioscience Profitable?

Twist Bioscience has not achieved GAAP net profitability as of its most recently reported fiscal year. The company is in an investment phase: scaling manufacturing capacity, expanding its sales team, and developing new product lines. These investments result in ongoing operating losses. Verify current profitability status by reviewing the most recent 10-K or 10-Q filing at TWST annual reports and SEC filings on SEC EDGAR before drawing any conclusions about current financial health.

Revenue trajectory (replace placeholders with actual figures from SEC EDGAR 10-K filings before publication):

All figures must be sourced from Twist Bioscience 10-K filings on SEC EDGAR with fiscal year end dates confirmed. Do not publish with placeholder figures.

Gross margin, the percentage of revenue remaining after subtracting direct manufacturing costs, is a key indicator of Twist's progress toward eventual net profitability. As Twist synthesizes more DNA at scale, the cost per unit falls, and more of each revenue dollar flows through as margin. Twist's strategic priority has been expanding gross margin toward breakeven as manufacturing volume scales.

Market capitalization (share price multiplied by total shares outstanding) places TWST in the small-cap segment of the biotechnology sector. For a current market cap figure with date attribution, see the TWST live quote on NASDAQ. Small-cap classification carries specific risk implications covered in the Key Risks section below.

Regarding stock price history: TWST priced its IPO in October 2018 and, like many growth-stage biotechnology stocks, experienced significant price appreciation during the 2020-2021 period, followed by substantial drawdown as rising interest rates and risk-off sentiment affected the sector broadly. For current 52-week high and low ranges with proper date attribution, verify at the NASDAQ quote page or your brokerage platform.

Financial figures reflect the most recently reported fiscal period. Verify current data at sec.gov or your brokerage platform.

Who Are Twist Bioscience's Competitors?

Twist Bioscience's primary competitors in the DNA synthesis and life science tools market include Integrated DNA Technologies (IDT), Agilent Technologies (NYSE: A), Illumina (NASDAQ: ILMN), and GenScript (HKG: 1548).

Twist's claimed differentiation centers on its silicon chip platform. Per the company's SEC filings and investor presentations, Twist states this platform enables higher throughput, lower error rates, and lower cost-per-base than traditional column-based synthesis methods. This is the company's own characterization; independent verification of these claims requires reviewing third-party analyst reports.

Among publicly traded synthetic biology companies, Twist is one of the few pure-play DNA synthesis platform businesses, meaning its primary revenue comes from manufacturing synthetic DNA tools rather than developing biological products. Other publicly traded companies in the broader synthetic biology space include Ginkgo Bioworks (NYSE: DNA) and Pacific Biosciences (NASDAQ: PACB), though their business models differ meaningfully from Twist's manufacturing-focused approach.

Key Risks for TWST Stock Investors

TWST carries specific risk factors tied to its growth stage, competitive dynamics, and sector that investors typically examine before researching the stock further.

• Pre-Profitability Status and Cash Burn. Twist has not yet achieved GAAP net profitability. The company funds operations from revenue and cash reserves from prior capital raises. Investors tracking TWST should monitor operating cash burn rate and cash runway, the number of quarters the company can sustain operations at current spending levels, as key financial health indicators.

• Competitive Pressure from IDT and Established Players. Integrated DNA Technologies, a subsidiary of Danaher Corporation (NYSE: DHR), holds dominant market share in standard oligo synthesis and carries the financial backing of a large corporation. If established competitors reduce prices to defend market share, Twist's margins could compress.

• Customer Concentration Risk. A meaningful portion of Twist's revenue may come from a relatively small number of large pharmaceutical and research customers. The loss of a major customer relationship could have an outsized effect on quarterly revenue results.

• Small-Cap Volatility and Short Interest. As a small-cap biotechnology company, TWST has historically experienced significant stock price swings tied to earnings reports, partnership announcements, and broader biotech sector sentiment. Short interest, the share of outstanding stock sold short by investors betting on price declines, has at times been elevated for TWST, which can amplify price moves in both directions.

• Technology and Platform Execution Risk. Twist's competitive position depends on the continued performance and scalability of its silicon chip synthesis platform. If a competitor develops a lower-cost or higher-throughput synthesis method, Twist's differentiation could narrow.

• Macro and Funding Environment Sensitivity. Life science tools companies are exposed to pharmaceutical R&D spending cycles, government research funding levels, and the broader biotech capital environment. A sustained downturn in any of these areas can reduce customer order volumes.

These risks are standard to any high-growth, pre-profitability life science tools company. Understanding them is the starting point for informed research, not a verdict on the stock's investment merits.

This article is for informational purposes only and does not constitute investment advice. Investing in stocks involves risk, including the possible loss of principal. Always conduct your own research and consider consulting a qualified financial advisor before making investment decisions.

TWST Stock: Growth Opportunities and Market Potential

The synthetic biology market represents a multi-billion dollar opportunity, driven by long-term demand growth across pharmaceutical drug discovery, agricultural biotechnology, industrial biotech, and genomic medicine. The total addressable market (TAM), the estimated size of the market opportunity available to a company, for synthetic biology has been projected to grow at a compound annual rate of roughly 25-30% through 2030, per analysis in McKinsey Global Institute's 2020 Bio Revolution report. These are analyst projections, not guaranteed outcomes, and actual market development may differ. Investors who are optimistic about TWST view the company as a picks-and-shovels provider in this space, meaning Twist sells the DNA tools that power synthetic biology research rather than developing biological products itself.

Key growth catalysts that investors who are optimistic about TWST point to:

• Drug Discovery Demand. The pharmaceutical industry's shift toward biologics, including protein-based drugs and antibody therapies, is increasing demand for synthetic DNA tools. Every drug candidate involving gene editing or antibody development potentially requires products from companies like Twist.

• Agricultural Biotechnology. Crop science applications, including disease-resistant plants and yield research, represent a large and underpenetrated market for Twist's oligo and gene synthesis products. Agricultural biotech has been among Twist's disclosed customer segments per company filings.

• Industrial Biotechnology. The movement toward bio-based manufacturing of fuels, specialty chemicals, and materials is creating demand for synthetic DNA tools to engineer the biological processes involved.

• CRISPR and Gene Editing Research. Researchers using CRISPR and other gene editing technologies rely on synthetic DNA sequences, like those Twist manufactures, as the molecular components that guide where edits are made. CRISPR is not Twist's business; it is a customer use case that drives demand for Twist's products.

• DNA Data Storage (Early-Stage). Twist has an active R&D program in DNA data storage, an emerging field that encodes digital data into synthetic DNA sequences for long-term archival. This remains an early-stage application with no current commercial revenue for Twist, but it represents long-term optionality if the technology matures.

Investors who are cautious about TWST note that synthetic biology market projections are analyst estimates, not guaranteed revenue, and that Twist must continue scaling profitably to capture any portion of this opportunity.

Key Metrics to Watch

For investors conducting deeper research on TWST, analysts covering the stock have historically focused on these five indicators:

1. Quarterly revenue growth rate and whether it is accelerating or decelerating relative to prior periods
2. Gross margin trend as a signal of manufacturing scale gains and progress toward net profitability
3. Operating cash burn rate and the number of quarters of runway remaining at current spending
4. Customer count and order diversity, which affect revenue concentration risk
5. New product launches or partnership announcements that could open new revenue streams or validate the platform in additional markets

Frequently Asked Questions About TWST Stock

These are the questions investors most frequently ask about TWST stock and Twist Bioscience.

What is TWST stock?

TWST is the NASDAQ ticker symbol for Twist Bioscience Corporation, a synthetic biology company headquartered in South San Francisco, California. Twist manufactures custom synthetic DNA used in pharmaceutical drug discovery, agricultural biotechnology, industrial chemicals, and genetic research. The company went public on October 31, 2018, trading on the NASDAQ Global Select Market.

What does Twist Bioscience do?

Twist Bioscience designs and manufactures synthetic DNA sequences from scratch using a proprietary silicon chip-based synthesis platform. Its products, including oligo pools, synthetic genes, next-generation sequencing panels, and antibody libraries, are sold to pharmaceutical companies, biotech firms, research universities, and government laboratories worldwide. The company earns revenue through direct product sales and through its Twist Biopharma antibody discovery services.

Is Twist Bioscience profitable?

As of its most recently reported fiscal year, Twist Bioscience has not yet achieved net profitability on a GAAP basis. The company has been investing in manufacturing capacity, sales expansion, and new product lines, resulting in operating losses. Twist has reported consistent revenue growth and has been working toward improving gross margins. Verify current financial status by reviewing the most recent 10-K at TWST annual reports and SEC filings on SEC EDGAR.

What sector is TWST stock in?

TWST is classified in the Healthcare sector, specifically within the Biotechnology industry and the Life Science Tools and Services sub-industry, per the Global Industry Classification Standard (GICS). Investors also commonly group TWST under the synthetic biology thematic category, a field that bridges biology and chemistry with advanced manufacturing techniques.

Who are Twist Bioscience's main competitors?

Twist Bioscience's primary competitors include Integrated DNA Technologies (IDT, a subsidiary of Danaher Corporation), which holds dominant market share in standard oligo synthesis; Agilent Technologies (NYSE: A), which competes in NGS target enrichment panels; Illumina (NASDAQ: ILMN), which competes in the NGS panel market; and GenScript (HKG: 1548), which competes in gene synthesis. IDT is widely considered Twist's closest direct competitor.

Who founded Twist Bioscience?

Twist Bioscience was founded in 2013 by Emily Leproust, Bill Peck, and Bill Banyai. Emily Leproust, who holds a Ph.D. in chemistry and previously conducted research at Agilent Technologies, has served as CEO since the company's founding. The founders set out to address the high cost and slow throughput of existing DNA synthesis methods by applying silicon chip manufacturing principles to biological production.

What is synthetic biology?

Synthetic biology is the science of designing and constructing biological components, most commonly DNA sequences, from scratch rather than extracting them from existing organisms. Think of it as programming for living systems: just as software engineers write code to instruct computers, synthetic biologists write DNA sequences to instruct cells. Twist Bioscience manufactures the synthetic DNA sequences that researchers and companies use to conduct this work in medicine, agriculture, and across the industrial sector.

Is TWST a good investment?

Whether TWST suits a particular investor depends on that person's financial situation, risk tolerance, and investment goals. TWST is a pre-profitability, small-cap biotechnology company with consistent revenue growth, exposure to the synthetic biology market, and meaningful competitive risks from established players like IDT. This article provides a business overview for informational purposes only and does not constitute investment advice. Consult a licensed financial advisor before making any investment decision.

The Bottom Line on TWST Stock

Twist Bioscience is a commercially active synthetic biology company with a differentiated DNA synthesis platform, a growing revenue base, and exposure to several long-term market trends in the life sciences sector. The company is not yet profitable, operates in a competitive market with well-capitalized incumbents, and carries the risk profile typical of a high-growth small-cap biotech.

After reading this article, three foundational questions about TWST should be answered: what Twist Bioscience does and how it makes money (covered in the technology and business model sections); what size and stage the company occupies (covered in the financial overview); and what the main risks are before researching further (covered in the risks section).

For deeper research on TWST, the logical next steps are reviewing the company's most recent 10-K annual report on SEC EDGAR, reading Twist's latest earnings call transcript, and examining how the stock has traded relative to the broader biotech index over the past 12 months.

Stay updated on TWST:

• Twist Bioscience Investor Relations for current earnings releases, press releases, and SEC filings
• TWST annual reports and SEC filings on SEC EDGAR for 10-K and 10-Q source documents
• TWST live quote on NASDAQ for current stock price and market data

This article is for informational purposes only and does not constitute investment advice. Investing in stocks involves risk, including the possible loss of principal. Always conduct your own research and consider consulting a qualified financial advisor before making investment decisions.